Douglas T. Sheehy files SEC Form 4 disclosures for Aimmune Therapeutics, Inc.. They have made 15 open-market trades across 2 companies since 2010, most recently 2020-10-13.
CIK 0001488637
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $8K since 2010, against 14 sales. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| AIMT | SELL · 10b5-1 | 2020-01-16 | 2020-01-21 | $37.00 | $15K | -6.7% | -17.7% | -49.3% |
| AIMT | SELL | 2019-12-26 | 2019-12-30 | $33.03 | $330K | -7.0% | -3.6% | -56.7% |
| AIMT | SELL | 2018-05-22 | 2018-05-24 | $33.00 | $54K | -5.7% | -17.3% | -16.4% |
| AIMT | SELL | 2018-03-05 | 2018-03-06 | $36.52 | $129K | -4.3% | -11.5% | -3.7% |
| AIMT | SELL | 2018-02-05 | 2018-02-07 | $35.87 | $118K | -7.1% | -10.6% | -17.6% |
| AIMT | SELL | 2018-01-24 | 2018-01-26 | $38.15 | $143K | +1.4% | -18.8% | -15.0% |
| AIMT | SELL | 2018-01-04 | 2018-01-08 | $37.33 | $123K | +1.7% | -1.7% | -21.0% |
| AIMT | SELL | 2017-12-26 | 2017-12-28 | $39.44 | $74K | +0.3% | -6.3% | -17.9% |
| AIMT | SELL | 2017-12-04 | 2017-12-06 | $38.66 | $147K | +2.3% | +8.6% | -5.0% |
| AIMT | SELL | 2017-11-30 | 2017-12-04 | $37.00 | $139K | -9.0% | +0.2% | -3.3% |
| AIMT | SELL | 2017-11-09 | 2017-11-13 | $33.00 | $63K | +3.6% | +2.1% | +12.1% |
| AIMT | SELL | 2017-10-23 | 2017-10-25 | $34.10 | $1.4M | -1.3% | +15.1% | +22.0% |
| AIMT | SELL | 2017-10-23 | 2017-10-25 | $34.51 | $2.0M | -1.3% | +15.1% | +22.0% |
| AIMT | SELL | 2017-07-21 | 2017-07-21 | $21.66 | $323K | -6.9% | -11.7% | +18.0% |
| CDXS | SELL | 2012-09-14 | 2012-09-14 | $2.76 | $10K | -1.7% | +1.7% | +1.7% |
| CDXS | BUY | 2010-08-10 | 2010-08-11 | $7.99 | $8K | -1.7% | +1.7% | +1.7% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.